Bristol Myers Squibb
↗Princeton, New Jersey, United States
Bristol Myers Squibb is a leading global biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines in oncology, immunology, cardiovascular disease, and neuroscience. The company was formed through the 1989 merger of Bristol-Myers (founded 1898) and Squibb Corporation (founded 1858), and subsequently acquired Celgene in 2019 for $74 billion, transforming itself into a major player in specialty pharmaceuticals. With revenues of $48.3 billion in 2024, BMS operates a 'Growth Portfolio' strategy emphasizing newer assets while navigating significant patent cliffs affecting legacy blockbusters like Eliquis and Revlimid.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Specialty Biopharmaceuticals
SIZE & FINANCIALS
Employees:10000+
Revenue:$48B
Founded:1989
Ownership:public
Status:operating
FUNDING
Stage:N/A
STOCK
Exchange:NYSE
Ticker:BMY
Market Cap:$106.4B
PIPELINE
Stage:Phase 1-3 and Commercial
Lead Drug Stage:Commercial (Opdivo, Breyanzi, Reblozyl, Cobenfy)
Modalities:Small molecule, Monoclonal antibody (mAb), Bispecific antibody, CAR-T cell therapy, Radiopharmaceutical
Trial Phases:-
FDA Approvals:50
EMA Approvals:30
CORPORATE STRUCTURE
Subsidiaries:Celgene (acquired 2019, $74B), MyoKardia (acquired 2020, $13.1B), Turning Point Therapeutics (acquired 2022), RayzeBio (acquired 2024, radiopharmaceuticals), Mirati Therapeutics (acquired 2024, $4.8B + $1B milestones), Karuna Therapeutics (acquired 2024, $14B), Orbital Therapeutics (acquired 2025, $1.5B), 2seventy bio (acquired 2024, $286M)
Key Partnerships:BioNTech - $1.5B upfront + $2B non-contingent payments for co-development of BNT327 bispecific antibody (2025), Insitro - AI drug discovery partnership for ALS research, up to $20M additional investment, total deal value >$2B (2025), Harbour BioMed - $90M+ for multi-specific antibody discovery and development (December 2025), Bain Capital - NewCo immunology joint venture with $300M funding for autoimmune disease therapies (2025), Merck - Co-commercialization partner for Reblozyl, Zai Lab - Expanded collaboration for oncology products in China, Prothena - Alliance for BMS-986495 in Alzheimer's/neurodegenerative diseases
COMPETITION
Position:Leader
Competitors:Johnson & Johnson, Pfizer, Merck & Co., Roche, Novartis, AbbVie, Eli Lilly, GlaxoSmithKline +2 more
LEADERSHIP
Key Executives:
Christopher Boerner, PhD - Board Chair and Chief Executive Officer
David V. Elkins - Executive Vice President and Chief Financial Officer
Sandra Leung - Executive Vice President, General Counsel
Robert Plenge, MD, PhD - Chief Research Officer, Executive Vice President
Amanda Poole - Executive Vice President, Chief People Officer
Karin Shanahan - Executive Vice President, Chief Supply Chain & Operations Officer
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Bristol Myers Squibb. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.